Related Experiment Videos
Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects
Insights
Synthetic atrial natriuretic polypeptide (ANP) improved left ventricular function in congestive heart failure (CHF) patients by reducing pulmonary capillary wedge pressure and systemic resistance, mainly through vasodilation.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Congestive heart failure (CHF) is a complex syndrome characterized by impaired cardiac function.
- Atrial natriuretic polypeptide (ANP) is a hormone with known vasodilatory and diuretic properties.
Purpose of the Study:
- To investigate the effects of synthetic alpha-human atrial natriuretic polypeptide (ANP) infusion on cardiovascular and renal function in patients with and without CHF.
- To determine if ANP improves left ventricular function in CHF patients.
Main Methods:
- Synthetic ANP was infused at 0.1 microgram/kg/min in patients with New York Heart Association class III or IV CHF and in healthy controls.
- Hemodynamic parameters (pulmonary capillary wedge pressure, stroke volume index, total systemic resistance) and renal function markers (urine volume, sodium excretion, creatinine clearance) were monitored.
Main Results:
- ANP infusion significantly decreased pulmonary capillary wedge pressure and total systemic resistance in both CHF and non-CHF groups.
- Stroke volume index increased significantly in CHF patients but not in non-CHF patients.
- ANP increased urine volume, sodium excretion, and creatinine clearance in non-CHF patients, with a similar trend in CHF patients.
Conclusions:
- Synthetic ANP infusion improves left ventricular function in CHF patients, primarily due to its vasodilating effects.
- ANP demonstrates potential as a therapeutic agent for managing CHF by improving cardiac performance and reducing vascular resistance.
Abstract:
Synthetic alpha-human atrial natriuretic polypeptide was infused in patients with congestive heart failure (CHF) (New York Heart Association class III or IV) and in those without CHF. The infusion of atrial natriuretic polypeptide (ANP) at a rate of 0.1 microgram/kg/min significantly decreased pulmonary capillary wedge pressure and increased stroke volume index in all of the patients with CHF, whereas it decreased pulmonary capillary wedge pressure but caused no significant change in stroke volume index in the patients without CHF. Concomitant significant reductions in total systemic resistance were observed in both groups of patients. The ANP infusion significantly increased the urine volume, the excretion of sodium, and endogenous creatinine clearance in the patients without CHF. In the patients with CHF, it also showed a tendency to increase all these variables, but the urine volume did not correlate with the reduction in pulmonary capillary wedge pressure. The ANP infusion also decreased plasma aldosterone concentrations in these patients, although no significant difference was observed in the decrement of the plasma aldosterone concentration in the patients with and those without CHF. These findings indicate that the ANP infusion improves left ventricular function in patients with CHF, and suggest that this improvement results mainly from the vasodilating activity of ANP.